Figure 7J summarizes the overall findings, demonstrating that in KRAS-G12C mutant NSCLC, the combination of G12Ci sotorasib and WEE1i adavosertib synergistically suppresses the MYBL2-RRM2 axis. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.